Source-grounded facts extracted from Glucotrack, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Glucotrack, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March 31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’”
Glucotrack, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 11, 2026, Glucotrack, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company”
Glucotrack, Inc. entered into Exchange Agreement with an investor (effective 2026-04-29).
“On April 29, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor in the principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (as modified, the “Original Note”).”
Glucotrack, Inc. entered into Exchange Agreement with an investor (the "Investor") (effective 2026-04-13).
“On April 13, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note (the “Original Note”) previously issued to the Investor in the principal amount of $3,600,000.”
Glucotrack, Inc. incurred loan of $600,000.
“On April 13, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note (the “Original Note”) previously issued to the Investor in the principal amount of $3,600,000. Pursuant to the Exchange Agreement, the Company and the Investor partitioned a new promissory note in the original principal amount of $600,000 (the “Partitioned Note”) from the Original Note.”
Glucotrack, Inc. reported full year ended December 31, 2025 results: net income Net loss for the full year 2025 was $19.4 million.
“Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025.”
Glucotrack, Inc. entered into Securities Purchase Agreement with an investor valued at approximately $4.0 million (effective 2025-12-29).
“On December 29, 2025, Glucotrack, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”) for a private placement of securities”
Glucotrack, Inc. incurred convertible notes of $3,600,000 at no interest maturing twelve (12) month anniversary of the Issue Date, or the date of closing of a Qualified Financing.
“On September 12, 2025 (the “ Issue Date ”), Glucotrack, Inc. (the “ Company ”) entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”), with an investor (the “ Investor ”), pursuant to which the Company issued a Convertible Promissory Note (the “ Note ”) to the Investor in the principal amount of $3,600,000 for a purchase price of $3,000,000.”
Glucotrack, Inc. engaged CBIZ CPAs P.C. as its auditor.
“pproved the engagement of CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent registered public accounting firm for”
Glucotrack, Inc. dismissed Grant Thornton as its auditor.
“On July 18, 2025, the Company dismissed Grant Thornton as the Company’s independent registered public accounting firm, effective immediately.”
Glucotrack, Inc. engaged CBIZ CPAs P.C. as its auditor.
“approved the engagement of CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent registered public accounting firm for the Company’s fiscal year ended December 31, 2025, effective July 18, 2025.”
Glucotrack, Inc. dismissed Fahn Kanne & Co. Grant Thornton Israel as its auditor.
“On July 18, 2025, the Company dismissed Fahn Kanne & Co. Grant Thornton Israel (“Grant Thornton”) as the Company’s independent registered public accounting firm, effective immediately.”
Glucotrack, Inc.: Effected a one-for-sixty reverse stock split via Certificate of Amendment to Certificate of Incorporation (effective 2025-06-13).
“Glucotrack, Inc., a Delaware corporation (the “Company”), filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Certificate of Amendment”), which became effective at 4:30 p.m. on June 13, 2025 (the “Effective Time”), to effect a one-for-sixty (1:60) reverse stock split”
Peter C. Wulff was appointed as Chief Financial Officer at Glucotrack, Inc..
“In connection with Mr. Cardwell’s resignation, on January 28, 2025, the Board appointed Peter C. Wulff as Chief Financial Officer of the Company.”
James Cardwell resigned as Chief Financial Officer at Glucotrack, Inc..
“On January 27, 2025, James Cardwell informed the Board of Directors (the “Board”) of Glucotrack, Inc. (the “Company”) that he was resigning as Chief Financial Officer of the Company, effective immediately.”
John Ballantyne was appointed as director at Glucotrack, Inc..
“On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.”
Paul V. Goode was appointed as director at Glucotrack, Inc..
“On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.”
Andrew Sycoff resigned as Director at Glucotrack, Inc..
“On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.”
Shimon Rapp resigned as Director at Glucotrack, Inc..
“On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.”
Andrew K. Balo was appointed as independent board member at Glucotrack, Inc..
“On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.”
Glucotrack, Inc. shareholders voted on Frequency of Non-Binding Advisory Votes on Executive Compensation at the 2024-04-26 meeting.
“Proposal 5 – Frequency of Non-Binding Advisory Votes on Executive Compensation The Company’s stockholders indicated, on an advisory basis, the preferred frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers as follows: Every One (1) Year Every Two (2) Years Every Three (3) Years Abstentions 2,213,593 531,688 8,138,410 5,154,080”
Glucotrack, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2024-04-26 meeting.
“Proposal 4 – Ratification of Independent Registered Public Accountant The Company’s stockholders ratified the previous appointment by the Audit Committee of the Board of Fahn Kanne & Co”
Glucotrack, Inc. shareholders approved Reverse Stock Split at the 2024-04-26 meeting.
“Proposal 3 – Reverse Stock Split The Company’s stockholders approved of an amendment to Article IV of the Company’s Certificate of Incorporation”
Glucotrack, Inc. shareholders approved Election of Directors at the 2024-04-26 meeting.
“The final results of the voting were as follows: Director Votes For Votes Against Abstentions Broker Non-Vote Dr. Robert Fischell 10,793,666 134,682 5,109,423 1,932,226 Luis Malave 10,793,666 122,745 5,121,360 1,932,226 Andrew Sycoff 10,805,663 5,231,471 637 1,932,226 Shimon Rapps 10,786,853 5,231,531 19,387 1,932,226 Allen Danzig 10,793,726 122,685 5,121,360 1,932,226 Erin Carter 10,793,806 122,745 5,121,220 1,932,226”
Glucotrack, Inc. shareholders approved 2024 Equity Incentive Plan at the 2024-04-26 meeting.
“Proposal 1 – 2024 Equity Incentive Plan The Company’s 2024 Equity Incentive Plan was approved. The final results of the voting were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,989,257 885,365 5,163,149 1,932,226”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.